| A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis (NCT05052983) | Galderma R&D | 2022-01-24 |
| A Study of CDX-0159 in Patients With Prurigo Nodularis (NCT04944862) | Celldex Therapeutics | 2021-11-08 |
| A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis (NCT05061693) | Incyte Corporation | 2021-11-04 |
| Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin (NCT05038982) | Johns Hopkins University | 2021-09-09 |
| China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project (NCT05316805) | Peking University First Hospital | 2021-08-31 |
| Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing (NCT04681300) | Assistance Publique - Hôpitaux de Paris | 2021-02-01 |
| A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04204616) | Galderma R&D | 2021-01-11 |
| Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666) | Galderma R&D | 2020-09-11 |
| A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679) | Galderma R&D | 2020-08-11 |
| Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis (NCT03816891) | Genentech, Inc. | 2019-03-11 |
| Pain Outcomes Following Intralesional Corticosteroid Injections (NCT03630198) | Vanderbilt University Medical Center | 2018-10-01 |
| Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis (NCT03677401) | Vyne Therapeutics Inc. | 2018-08-29 |
| PRISM Study-Pruritus Relief Through Itch Scratch Modulation (NCT03497975) | Trevi Therapeutics | 2018-08-07 |
| Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis (NCT03546816) | Vyne Therapeutics Inc. | 2018-05-02 |
| Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) (NCT03540160) | Vyne Therapeutics Inc. | 2018-03-15 |
| Safety and Efficacy of Nemolizumab in PN (NCT03181503) | Galderma R&D | 2017-10-02 |
| Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis (NCT03576287) | Tanja Todberg, MD | 2017-07-01 |
| Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis (NCT02174432) | Trevi Therapeutics | 2015-08-15 |
| Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis (NCT02174419) | Trevi Therapeutics | 2015-03-01 |
| A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) (NCT02196324) | Vyne Therapeutics Inc. | 2014-07-09 |
| Safety and Efficacy of CC-10004 for Prurigo Nodularis (NCT00869089) | University Hospitals Cleveland Medical Center | 2008-09-01 |
| Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease (NCT00507832) | University Hospital Muenster | 2007-04-01 |
| Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis (NCT00532519) | Hadassah Medical Organization | |